Ireland-based medical technology company Medtronic has obtained CE mark for its range of cardiac resynchronisation therapy pacemakers (CRT-Ps) that enable proactive heart failure management.
To be available in Europe from March, the range includes Percepta Quad CRT-P MRI SureScan, Serena Quad CRT-P MRI SureScan and Solara Quad CRT-P MRI SureScan.
These devices allow magnetic resonance imaging (MRI) scanning in either 1.5 or 3 Tesla (T) machines.
Equipped with the EffectivCRT Diagnostic, the Percepta Quad CRT-P can determine the effectiveness of each left ventricular pace and the EffectivCRT during AF algorithm automatically adjusts pacing rates during atrial fibrillation (AF).
The Percepta also features an automated in-office test called VectorExpress 2.0 that decreases lead programing to two minutes and provides clinical information to aid physicians in deciding optimal pacing configurations for each patient.
Both Percepta Quad and Serena Quad CRT-Ps also include the AdaptivCRT algorithm, which is reported to decrease the chance of a patient's readmission due to a 30 day heart failure by 59%.
The algorithm is also reported to reduce the AF risk by 46%, when compared to echo-optimised biventricular pacing.
The Percepta and Serena additionally include Multiple Point Pacing that allows simultaneous or sequential stimulation of two sites on the left ventricle.
All the three pacemakers feature the Attain Perfoma MRI SureScan Quadripolar Leads that has short bipolar spacing to decrease phrenic nerve stimulation occurrence, steroid on all electrodes and comes in three shapes for different patient anatomies.
They also include SureScan MR-conditional labeling that facilitates full-body scans without positioning restrictions.